PRESS RELEASE

Basilea announces completion of patient enrolment in phase 1 study with oral BAL101553 in brain cancer

Basel, Switzerland, August 27, 2019 – Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the completion of patient enrolment in its phase 1 study with the oral formulation of the novel tumor checkpoint controller BAL101553 in brain cancer patients.  

The study included 28 patients with progressive or recurrent glioblastoma (GBM), the most aggressive primary brain tumor, or high-grade glioma. Patients received once-daily oral BAL101553. The maximum tolerated dose (MTD) was determined at 30 mg per day. Dose-limiting adverse events included gait disturbances, hallucinations and confusion, which were all reversible.  

Dose levels up to and including 25 mg per day were well tolerated. Clinical antitumor activity of BAL101553 was shown with one exceptional, long-lasting responder still on treatment, whose brain tumor tissue displayed strong expression of the potentially response-predictive biomarker EB1 (end-binding protein 1). In addition, five further patients experienced stable disease as a best response.  

Dr. Marc Engelhardt, Basilea’s Chief Medical Officer, said: “The results from the phase 1 study in brain cancer patients indicate a manageable safety and tolerability profile, which is consistent with the safety profile observed for BAL101553 in the treatment of other advanced solid tumors. The observation of an exceptional, durable response in a GBM patient whose tissue was strongly positive for EB1 is encouraging, especially as we had previously identified EB1 as a potential response-predictive biomarker for BAL101553 based on comprehensive preclinical studies in GBM models. We are now assessing the potential utility of EB1 to support a biomarker-driven clinical study with BAL101553 in GBM and other cancer types. This would subsequently allow using BAL101553 as a targeted therapy in patients whose tumors show high EB1 expression.”

About BAL101553

Basilea’s oncology drug candidate BAL101553 (the prodrug of BAL27862) is being developed as a potential therapy for diverse cancers. In addition to the study described in this press release, there are two more clinical studies ongoing. In Switzerland, a phase 2a expansion study is exploring the drug in recurrent glioblastoma and platinum-resistant ovarian cancer patients using weekly 48-hour infusion. In the U.S., a phase 1 study is being conducted in collaboration with the Adult Brain Tumor Consortium (ABTC), in which BAL101553 is explored in combination with radiotherapy in patients with newly diagnosed glioblastoma who have a reduced sensitivity to chemotherapy with the standard-of-care drug temozolomide. Preclinical studies, BAL101553 demonstrated in-vitro and in-vivo activity against diverse treatment-resistant cancer models, including tumors refractory to conventional approved therapeutics and radiotherapy. BAL101553 efficiently distributes to the brain, with anticancer activity in glioblastoma models. In preclinical studies, end-binding protein 1 (EB1) was identified as a potential response-predictive biomarker in glioblastoma models. The active moiety BAL27862 binds to the colchicine site of tubulin, with distinct effects on microtubule organization, resulting in the activation of the “spindle assembly checkpoint” which promotes tumor cell death.

About Basilea

Basilea Pharmaceutica Ltd. is a commercial stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of...
oncology and anti-infectives. With two commercialized drugs, the company is committed to
discovering, developing and commercializing innovative pharmaceutical products to meet the
medical needs of patients with serious and life-threatening conditions. Basilea Pharmaceutica
Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN).
Additional information can be found at Basilea's website www.basilea.com.

Disclaimer
This communication expressly or implicitly contains certain forward-looking statements, such as
"believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar
expressions concerning Basilea Pharmaceutica Ltd. and its business, including with respect to
the progress, timing and completion of research, development and clinical studies for product
candidates. Such statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition, performance or achievements
of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica
Ltd. is providing this communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new information, future events or
otherwise.

For further information, please contact:
Peer Nils Schröder, PhD
Head of Corporate Communications & Investor Relations
+41 61 606 1102
media_relations@basilea.com
investor_relations@basilea.com

This press release can be downloaded from www.basilea.com.

References
1 ClinicalTrials.gov identifier: NCT02490800
3 J. S. Lopez, R. Kristeleit, R. Rulach et al. Phase 1/2a study of once daily oral BAL101553, a novel tumor
checkpoint controller (TCC), in adult patients with progressive or recurrent glioblastoma (GBM) or high-
grade glioma. Journal of Clinical Oncology 2019; 37; 15 Supplement: 2025
4 J. Pohlmann, F. Bachmann, A. Schmitt-Hoffmann et al. BAL101553: An optimized prodrug of the
microtubule destabilizer BAL27862 with superior antitumor activity. American Association for Cancer
Research (AACR) annual meeting 2011, abstract 1347; Cancer Research 2011, 71 (8 Supplement)
5 ClinicalTrials.gov identifier: NCT02895360
6 ClinicalTrials.gov identifier: NCT03250299
7 A. Sharma, A. Broggini-Tenzer, V. Vuong et al. The novel microtubule targeting agent BAL101553 in
combination with radiotherapy in treatment-refractory tumor models. Radiotherapy Oncology 2017
(124), 433-438
8 G. E. Duran, H. Lane, F. Bachmann et al. In vitro activity of the novel tubulin active agent BAL27862 in
MDR1(+) and MDR1(-) human breast and ovarian cancer variants selected for resistance to taxanes.
American Association for Cancer Research (AACR) annual meeting 2010, abstract 4412; Cancer
Research 2010, 70 (8 Supplement)
9 F. Bachmann, K. Burger, G. E. Duran et al. BAL101553 (prodrug of BAL27862): A unique microtubule
destabilizer active against drug refractory breast cancers alone and in combination with trastuzumab.
American Association for Cancer Research (AACR) annual meeting 2014, abstract 831; Cancer
Research 2014, 74 (19 Supplement)
10 A. Schmitt-Hoffmann, D. Kraer, K. Gebhardt et al. BAL27862: a unique microtubule-targeted agent with
C233; Molecular Cancer Therapeutics 2009, 8 (12 Supplement)
11 A. C. Mladek, J. L. Pokorny, H. Lane et al. The novel tubulin-binding ‘tumor checkpoint controller’ BAL101553 has anti-cancer activity alone and in combination treatments across a panel of GBM patient-derived xenografts. American Association for Cancer Research (AACR) annual meeting 2016, abstract 4781; Cancer Research 2016, 76 (14 Supplement)

12 R. Bergès, A. Tchoghandjian, S. Honoré et al. The novel tubulin-binding checkpoint activator BAL101553 inhibits EB1-dependent migration and invasion and promotes differentiation of glioblastoma stem-like cells. Molecular Cancer Therapeutics 2016 (15), 2740-2749

13 A. E. Prota, F. Danel, F. Bachmann et al. The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization. Journal of Molecular Biology 2014 (426), 1848-1860

14 F. Bachmann, K. Burger, H. Lane. BAL101553 (prodrug of BAL27862): the spindle assembly checkpoint is required for anticancer activity. American Association for Cancer Research (AACR) annual meeting 2015, abstract 3789; Cancer Research 2015, 75 (15 Supplement)